Cingulate Inc (CING)

$4.83 +0.04 (0.84%)
Market Cap 64.52M
Revenue (ttm) 0.00
Net Income (ttm) -22.45M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 135,300
Avg Vol 494,970
Day's Range N/A - N/A
Shares Out 13.47M
Stochastic %K 81%
Beta -0.91
Analysts Strong Sell
Price Target $23.00

Company Profile

Cingulate Inc., a biopharmaceutical company, develops pharmaceutical products using its drug delivery platform technology for the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety in the United States. The company's lead product candidate is CTx-1301 (dexmethylphenidate), which is in Phase 3 clinical trials for the treatment of ADHD in children, adolescents, and adults. It also develops CTx-2103 (buspirone), which is in a formulation stage for the treatment of anxiety. In...

Industry: Biotechnology
Sector: Healthcare
Phone: 913 942 2300
Address:
1901 West 47th Place, Kansas City, United States
Spicy_Weeklies
Spicy_Weeklies Aug. 2 at 2:35 AM
$CING šŸ‚
0 Ā· Reply
Spicy_Weeklies
Spicy_Weeklies Aug. 2 at 2:35 AM
$CING Canā€™t wait for the day I wake up and this stock is up multi X. šŸ¤¤
0 Ā· Reply
ZacksResearch
ZacksResearch Jul. 31 at 2:25 PM
$CING just cleared a major credibility milestone šŸš€ Phase 3 results for CTx-1301 were published in a peer-reviewed journal, reinforcing its efficacy and safety profile as the company advances toward potential regulatory approval and commercialization. šŸ“Š All three dose groups beat placebo on the primary endpoint at Week 5 āœ… Clinically meaningful improvements in ADHD symptoms with a favorable safety profile šŸ’Š Once-daily treatment candidate powered by Precision Timed Releaseā„¢ (PTRā„¢) technology See what Wall Street expects next šŸ‘‰ https://www.zacks.com/stock/research/CING/price-target-stock-forecast?cid=sm-stocktwits-0-price_target-oc-39056&ADID=SYND_STOCKTWITS_TWEET_0_PRICETARGET_OC_39056
0 Ā· Reply
Merlintrader
Merlintrader Jul. 31 at 10:11 AM
$CING Cingulate Inc. Stock Hub: CTx-1301 Phase 3 Publication, the FDA CRL, Resubmission Timeline and Risks https://www.merlintrader.com/cingulate-inc-stock-hub/
0 Ā· Reply
Spicy_Weeklies
Spicy_Weeklies Jul. 30 at 9:36 PM
$CING https://www.linkedin.com/posts/indegene_were-excited-to-announce-bryan-downey-%F0%9D%97%96%F0%9D%97%B5%F0%9D%97%B6%F0%9D%97%B2%F0%9D%97%B3-activity-7487846833537302529-_TNo?utm_source=share&utm_medium=member_ios&rcm=ACoAAARnNc4BidxrJhqoExzyhnHvJzYovDFPXTs
0 Ā· Reply
LeoWhite961
LeoWhite961 Jul. 30 at 8:43 PM
$CING published Phase 3 ADHD trial results in a peer-reviewed journal. The study adds another layer of validation for Cingulateā€™s approach, but the next step is turning clinical data into commercial progress. In biotech, execution after the trial is just as important as the trial itself.
0 Ā· Reply
Hrk024
Hrk024 Jul. 30 at 8:04 PM
$CING "It's going to $3" Absolute šŸ¤”'s! Lol. Most of the swing traders are gone in my opinion so your little bear talk tactics are a joke and are not working. We will hang around here for time being and I'm perfectly okay with it.
1 Ā· Reply
prismmarketview
prismmarketview Jul. 30 at 5:59 PM
$CING Phase 3 pediatric ADHD data for onceā€‘daily CTxā€‘1301 are now published in a top child/adolescent psychopharm journal. Peerā€‘reviewed validation of earlier topline efficacy and safety results. #CING #StimulantTherapy #ChildPsychiatry https://prismmarketview.com/cingulates-phase-3-ctx-1301-adhd-results-published-in-leading-child-adolescent-psychiatry-journal/
0 Ā· Reply
Spicy_Weeklies
Spicy_Weeklies Jul. 30 at 3:37 PM
$CING Iā€™ve parked some patient money here and will hold out for the binary outcome. Not going to try and time anything based on how close they are to the finish line. The science works and the CMC issues are most likely solvable with timeline being the main variable. Demand for a solution like this will be strong, and I believe they could leverage AI tools to cut through some of the documentation enhancements. Iā€™m assuming modest competence in the teams that are working on the remediation work. Good luck to all. Fortune favors the brave.
0 Ā· Reply
RNJen
RNJen Jul. 30 at 12:55 PM
$CING KANSAS CITY, Kan. , July 30, 2026 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING ), a biopharmaceutical company utilizing its proprietary Precision Timed Releaseā„¢ (PTRā„¢) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, announced today that Phase 3 clinical trial results for its lead asset, CTx-1301 (dexmethylphenidate HCl), for the treatment of attention-deficit/hyperactivity disorder (ADHD), have been published in the Journal of Child and Adolescent Psychopharmacology and are now available through open access. The peer-reviewed publication helps establish the efficacy and safety profile of CTx-1301 and reinforces the potential of Cingulateā€™s Precision Timed Releaseā„¢ (PTRā„¢) platform technology, as the Company advances its lead asset toward potential regulatory approval and commercialization. The manuscript represents an important addition to the scientific literature supporting next-generation ADHD
1 Ā· Reply
Latest News on CING
Cingulate Announces Publication of Phase 3 ADHD Trial Results in Journal of Child and Adolescent Psychopharmacology

Jul 30, 2026, 8:30 AM EDT - 4 days ago

Cingulate Announces Publication of Phase 3 ADHD Trial Results in Journal of Child and Adolescent Psychopharmacology

Cingulate Inc. (NASDAQ: CING) Added to Russell 3000EĀ®

Jul 2, 2026, 8:30 AM EDT - 4 weeks ago

Cingulate Inc. (NASDAQ: CING) Added to Russell 3000EĀ®

Cingulate issues patent by USPTO for CTx-1301

2026-06-16T12:17:17.000Z - 6 weeks ago

Cingulate issues patent by USPTO for CTx-1301

Cingulate Issued First U.S. Patent for Lead ADHD Asset CTx-1301

Jun 16, 2026, 8:00 AM EDT - 6 weeks ago

Cingulate Issued First U.S. Patent for Lead ADHD Asset CTx-1301

Stonegate Capital Partners Updates Coverage on Cingulate Inc. (CING) 1Q26

Jun 4, 2026, 4:48 PM EDT - 2 months ago

Stonegate Capital Partners Updates Coverage on Cingulate Inc. (CING) 1Q26

Roth sees ā€˜major silver liningā€™ in Cingulate complete response letter

2026-06-04T10:50:56.000Z - 2 months ago

Roth sees ā€˜major silver liningā€™ in Cingulate complete response letter

Cingulate issued complete response letter for CTx-1301 from FDA

2026-06-02T13:17:58.000Z - 2 months ago

Cingulate issued complete response letter for CTx-1301 from FDA

US FDA declines to approve Cingulate's ADHD drug

Jun 2, 2026, 8:08 AM EDT - 2 months ago

US FDA declines to approve Cingulate's ADHD drug

Cingulate Receives Complete Response Letter from FDA for CTx-1301

Jun 2, 2026, 8:00 AM EDT - 2 months ago

Cingulate Receives Complete Response Letter from FDA for CTx-1301

Cingulate Proxy statement: Proxy filing

May 29, 2026, 8:00 AM EDT - 2 months ago

Cingulate Proxy statement: Proxy filing

Cingulate Proxy statement: Proxy filing

May 29, 2026, 8:00 AM EDT - 2 months ago

Cingulate Proxy statement: Proxy filing

Cingulate price target lowered to $10 from $14 at Roth Capital

2026-05-19T15:00:40.000Z - 2 months ago

Cingulate price target lowered to $10 from $14 at Roth Capital

Cingulate Proxy statement: Proxy filing

May 18, 2026, 8:00 AM EDT - 2 months ago

Cingulate Proxy statement: Proxy filing

Cingulate Inc. Reports First Quarter 2026 Financial Results and Provides an Update of Commercial Readiness Efforts On Track for lead ADHD Asset CTx-1301

May 14, 2026, 8:00 AM EDT - 2 months ago

Cingulate Inc. Reports First Quarter 2026 Financial Results and Provides an Update of Commercial Readiness Efforts On Track for lead ADHD Asset CTx-1301

Cingulate Earnings release: Q1 2026

May 14, 2026, 8:00 AM EDT - 2 months ago

Cingulate Earnings release: Q1 2026

Cingulate Quarterly report: Q1 2026

May 14, 2026, 8:00 AM EDT - 2 months ago

Cingulate Quarterly report: Q1 2026

Cingulate files to sell 4.21M shares of common stock for holders

2026-04-14T21:30:17.000Z - 3 months ago

Cingulate files to sell 4.21M shares of common stock for holders

Cingulate Registration statement: Registration filing

Apr 14, 2026, 8:00 AM EDT - 3 months ago

Cingulate Registration statement: Registration filing

Stonegate Capital Partners Updates Coverage on Cingulate Inc. (CING) 4Q25

Apr 6, 2026, 4:34 PM EDT - 4 months ago

Stonegate Capital Partners Updates Coverage on Cingulate Inc. (CING) 4Q25

Cingulate Slides: Corporate presentation

Apr 1, 2026, 7:00 AM EDT - 4 months ago

Cingulate Slides: Corporate presentation

Cingulate Registration statement: Registration filing

Mar 23, 2026, 8:00 AM EDT - 4 months ago

Cingulate Registration statement: Registration filing

Cingulate price target lowered to $14 from $16 at Roth Capital

2026-03-22T22:30:08.000Z - 4 months ago

Cingulate price target lowered to $14 from $16 at Roth Capital

Cingulate Registration statement: Registration filing

Mar 20, 2026, 8:00 AM EDT - 4 months ago

Cingulate Registration statement: Registration filing

Cingulate files to sell 3.5M shares of common stock for holders

2026-03-20T11:46:09.000Z - 4 months ago

Cingulate files to sell 3.5M shares of common stock for holders

Cingulate announces U.S. patent notice of allowance

2026-03-18T12:12:11.000Z - 4 months ago

Cingulate announces U.S. patent notice of allowance

Cingulate reports Q4 net loss $6.3M vs. $6.2M last year

2026-03-18T12:05:55.000Z - 4 months ago

Cingulate reports Q4 net loss $6.3M vs. $6.2M last year

Cingulate sees cash runway into late 4Q26

2026-03-18T12:05:40.000Z - 4 months ago

Cingulate sees cash runway into late 4Q26

Cingulate Proxy statement: Proxy Filing

Mar 18, 2026, 8:00 AM EDT - 4 months ago

Cingulate Proxy statement: Proxy Filing

Cingulate Earnings release: Q4 2025

Mar 18, 2026, 7:00 AM EDT - 4 months ago

Cingulate Earnings release: Q4 2025

Cingulate Annual report: Q4 2025

Mar 18, 2026, 7:00 AM EDT - 4 months ago

Cingulate Annual report: Q4 2025

Why did Cingulate stock skyrocket today?

Mar 16, 2026, 1:26 PM EDT - 5 months ago

Why did Cingulate stock skyrocket today?

Cingulate Proxy statement: Proxy Filing

Mar 2, 2026, 7:00 AM EST - 5 months ago

Cingulate Proxy statement: Proxy Filing

Cingulate Proxy statement: Proxy Filing

Feb 18, 2026, 7:00 AM EST - 5 months ago

Cingulate Proxy statement: Proxy Filing

Cingulate files $200M mixed securities shelf

2026-01-12T22:15:20.000Z - 7 months ago

Cingulate files $200M mixed securities shelf

Cingulate Registration statement: Registration Filing

Jan 12, 2026, 7:00 AM EST - 7 months ago

Cingulate Registration statement: Registration Filing

Cingulate price target lowered to $16 from $17 at Roth Capital

2025-11-19T12:40:10.000Z - 9 months ago

Cingulate price target lowered to $16 from $17 at Roth Capital

Cingulate price target lowered to $16 from $17 at Roth Capital

2025-11-19T00:55:07.000Z - 9 months ago

Cingulate price target lowered to $16 from $17 at Roth Capital

Stonegate Capital Partners Updates Coverage on Cingulate Inc. (CING) 3Q25

Nov 18, 2025, 4:27 PM EST - 9 months ago

Stonegate Capital Partners Updates Coverage on Cingulate Inc. (CING) 3Q25

Cingulate reports Q3 net loss ($7.3M) vs ($4.1M) last year

2025-11-13T13:16:41.000Z - 9 months ago

Cingulate reports Q3 net loss ($7.3M) vs ($4.1M) last year

Cingulate Quarterly report: Q3 2025

Nov 13, 2025, 8:00 AM EST - 9 months ago

Cingulate Quarterly report: Q3 2025

Cingulate Earnings release: Q3 2025

Nov 13, 2025, 8:00 AM EST - 9 months ago

Cingulate Earnings release: Q3 2025

Cingulate names Downey as CCO to lead launch prep for CTx-1301

2025-11-10T13:25:38.000Z - 9 months ago

Cingulate names Downey as CCO to lead launch prep for CTx-1301

Cingulate presents Phase 3 results for CTx-1301, met primary endpoint

2025-10-28T12:27:02.000Z - 9 months ago

Cingulate presents Phase 3 results for CTx-1301, met primary endpoint

Cingulate's Lead ADHD Candidate CTx-1301 Selected for Podium Presentation at AACAP Annual Meeting

Oct 23, 2025, 4:45 PM EDT - 10 months ago

Cingulate's Lead ADHD Candidate CTx-1301 Selected for Podium Presentation at AACAP Annual Meeting

Cingulate price target raised to $17 from $10 at Roth Capital

2025-10-15T01:25:08.000Z - 10 months ago

Cingulate price target raised to $17 from $10 at Roth Capital

Cingulate announces FDA accepted for review the NDA for CTx-1301

2025-10-14T12:05:41.000Z - 10 months ago

Cingulate announces FDA accepted for review the NDA for CTx-1301

Cingulate Secures Exclusive Manufacturing Partnership with Bend Bio Sciences to Support Future Commercialization of Next Generation ADHD Treatment

Sep 17, 2025, 8:45 AM EDT - 11 months ago

Cingulate Secures Exclusive Manufacturing Partnership with Bend Bio Sciences to Support Future Commercialization of Next Generation ADHD Treatment

Stonegate Capital Partners Updates Coverage on Cingulate Inc. (CING) 2Q25

Aug 21, 2025, 4:35 PM EDT - 1 year ago

Stonegate Capital Partners Updates Coverage on Cingulate Inc. (CING) 2Q25

Cingulate Inc. Reports Second Quarter 2025 Financial ResultsĀ and Provides Recent Highlights

Aug 19, 2025, 8:45 AM EDT - 1 year ago

Cingulate Inc. Reports Second Quarter 2025 Financial ResultsĀ and Provides Recent Highlights

Cingulate Quarterly report: Q2 2025

Aug 19, 2025, 7:00 AM EDT - 1 year ago

Cingulate Quarterly report: Q2 2025

Cingulate Earnings release: Q2 2025

Aug 19, 2025, 7:00 AM EDT - 1 year ago

Cingulate Earnings release: Q2 2025

Cingulate Provides Management Team Update

Aug 15, 2025, 9:00 AM EDT - 1 year ago

Cingulate Provides Management Team Update

Cingulate Proxy statement: Proxy Filing

Aug 15, 2025, 8:00 AM EDT - 1 year ago

Cingulate Proxy statement: Proxy Filing

Cingulate Submits New Drug Application to FDA for Lead ADHD Asset CTx-1301

Aug 6, 2025, 8:45 AM EDT - 1 year ago

Cingulate Submits New Drug Application to FDA for Lead ADHD Asset CTx-1301

Cingulate Proxy statement: Proxy Filing

Aug 5, 2025, 8:00 AM EDT - 1 year ago

Cingulate Proxy statement: Proxy Filing

Cingulate Registration statement: Registration Filing

Jul 25, 2025, 8:00 AM EDT - 1 year ago

Cingulate Registration statement: Registration Filing

Cingulate Registration statement: Registration Filing

Jul 22, 2025, 8:00 AM EDT - 1 year ago

Cingulate Registration statement: Registration Filing

Stonegate Capital Partners Initiates Coverage on Cingulate Inc. (CING)

Jun 18, 2025, 8:00 AM EDT - 1 year ago

Stonegate Capital Partners Initiates Coverage on Cingulate Inc. (CING)

Cingulate Inc. Reports First Quarter 2025 Financial Results and Provides an Updated Timeline of Key Developments for its lead ADHD and Anxiety Assets

May 8, 2025, 4:30 PM EDT - 1 year ago

Cingulate Inc. Reports First Quarter 2025 Financial Results and Provides an Updated Timeline of Key Developments for its lead ADHD and Anxiety Assets

Cingulate Earnings release: Q1 2025

May 8, 2025, 12:00 AM EDT - 1 year ago

Cingulate Earnings release: Q1 2025

Cingulate Quarterly report: Q1 2025

May 8, 2025, 12:00 AM EDT - 1 year ago

Cingulate Quarterly report: Q1 2025

Cingulate Proxy statement: Proxy Filing

Apr 28, 2025, 8:00 AM EDT - 1 year ago

Cingulate Proxy statement: Proxy Filing

Cingulate Proxy statement: Proxy Filing

Apr 25, 2025, 8:00 AM EDT - 1 year ago

Cingulate Proxy statement: Proxy Filing

Cingulate Proxy statement: Proxy Filing

Apr 15, 2025, 8:00 AM EDT - 1 year ago

Cingulate Proxy statement: Proxy Filing

Cingulate Receives $3 Million Grant from Private Foundation to Accelerate Development of Anxiety Asset CTx-2103 (buspirone)

Apr 9, 2025, 8:00 AM EDT - 1 year ago

Cingulate Receives $3 Million Grant from Private Foundation to Accelerate Development of Anxiety Asset CTx-2103 (buspirone)

Cingulate Inc. Reports Full Year 2024, Fourth Quarter Results,Ā and Provides Development Update on Major Milestones Achieved

Mar 26, 2025, 5:00 PM EDT - 1 year ago

Cingulate Inc. Reports Full Year 2024, Fourth Quarter Results,Ā and Provides Development Update on Major Milestones Achieved

Cingulate Annual report: Q4 2024

Mar 26, 2025, 9:00 AM EDT - 1 year ago

Cingulate Annual report: Q4 2024

Cingulate Earnings release: Q4 2024

Mar 26, 2025, 9:00 AM EDT - 1 year ago

Cingulate Earnings release: Q4 2024

Cingulate Completes Financing Transaction for Net Proceeds of $5,000,000

Dec 23, 2024, 7:30 AM EST - 1 year ago

Cingulate Completes Financing Transaction for Net Proceeds of $5,000,000

Cingulate Reports Third Quarter 2024 Financial ResultsĀ Reflecting $19.5 Million Increase in Working Capital to Advance ADHD Drug to Market

Nov 7, 2024, 7:30 AM EST - 1 year ago

Cingulate Reports Third Quarter 2024 Financial ResultsĀ Reflecting $19.5 Million Increase in Working Capital to Advance ADHD Drug to Market

Cingulate Quarterly report: Q3 2024

Nov 7, 2024, 7:00 AM EST - 1 year ago

Cingulate Quarterly report: Q3 2024

Cingulate Earnings release: Q3 2024

Nov 7, 2024, 7:00 AM EST - 1 year ago

Cingulate Earnings release: Q3 2024

Cingulate's Shane Schaffer Joins Cast of Nationally Syndicated Big Biz Show

Oct 8, 2024, 3:15 PM EDT - 1 year ago

Cingulate's Shane Schaffer Joins Cast of Nationally Syndicated Big Biz Show

Cingulate Registration statement: Registration Filing

Oct 7, 2024, 8:00 AM EDT - 1 year ago

Cingulate Registration statement: Registration Filing

Cingulate Registration statement: Registration Filing

Oct 3, 2024, 8:00 AM EDT - 1 year ago

Cingulate Registration statement: Registration Filing

Cingulate Registration statement: Registration Filing

Sep 27, 2024, 8:00 AM EDT - 2 years ago

Cingulate Registration statement: Registration Filing

Cingulate Initiates Final Study for Lead ADHD Asset CTx-1301

Sep 12, 2024, 8:30 AM EDT - 2 years ago

Cingulate Initiates Final Study for Lead ADHD Asset CTx-1301

Cingulate to Participate in Benzinga All Live Access Event

Aug 27, 2024, 4:30 PM EDT - 2 years ago

Cingulate to Participate in Benzinga All Live Access Event

Cingulate Announces Adjournment of Special Meeting

Aug 23, 2024, 4:45 PM EDT - 2 years ago

Cingulate Announces Adjournment of Special Meeting

Cingulate Proxy statement: Proxy Filing

Aug 23, 2024, 8:00 AM EDT - 2 years ago

Cingulate Proxy statement: Proxy Filing

Cingulate Registration statement: Registration Filing

Aug 19, 2024, 8:00 AM EDT - 2 years ago

Cingulate Registration statement: Registration Filing

Cingulate stock surges 115% after European patent approval for ADHD treatment: Is it a buy?

Aug 16, 2024, 12:36 PM EDT - 2 years ago

Cingulate stock surges 115% after European patent approval for ADHD treatment: Is it a buy?

Cingulate Issued European Patent for Lead Asset CTx-1301 for the Treatment of ADHD

Aug 15, 2024, 7:45 AM EDT - 2 years ago

Cingulate Issued European Patent for Lead Asset CTx-1301 for the Treatment of ADHD

Cingulate Reports Second Quarter 2024 Financial ResultsĀ and Provides Development Update on Major Milestones Achieved

Aug 13, 2024, 7:45 AM EDT - 2 years ago

Cingulate Reports Second Quarter 2024 Financial ResultsĀ and Provides Development Update on Major Milestones Achieved

Cingulate Quarterly report: Q2 2024

Aug 13, 2024, 7:00 AM EDT - 2 years ago

Cingulate Quarterly report: Q2 2024

Cingulate Earnings release: Q2 2024

Aug 13, 2024, 7:00 AM EDT - 2 years ago

Cingulate Earnings release: Q2 2024

Cingulate Proxy statement: Proxy Filing

Jul 22, 2024, 8:00 AM EDT - 2 years ago

Cingulate Proxy statement: Proxy Filing

Cingulate Registration statement: Registration Filing

Jul 15, 2024, 8:00 AM EDT - 2 years ago

Cingulate Registration statement: Registration Filing

Cingulate Proxy statement: Proxy Filing

Jul 12, 2024, 8:00 AM EDT - 2 years ago

Cingulate Proxy statement: Proxy Filing

Cingulate Proxy statement: Proxy Filing

Jul 12, 2024, 8:00 AM EDT - 2 years ago

Cingulate Proxy statement: Proxy Filing

Cingulate Announces Exercise of Warrants for $1.86 Million Gross Proceeds

Jun 28, 2024, 9:15 AM EDT - 2 years ago

Cingulate Announces Exercise of Warrants for $1.86 Million Gross Proceeds

Cingulate Proxy statement: Proxy Filing

Jun 28, 2024, 8:00 AM EDT - 2 years ago

Cingulate Proxy statement: Proxy Filing

Cingulate and ADHD Expert Dr. Ann Childress, MD to Participate in Benzinga All Live Access Event

Jun 25, 2024, 4:30 PM EDT - 2 years ago

Cingulate and ADHD Expert Dr. Ann Childress, MD to Participate in Benzinga All Live Access Event

Cingulate Achieves Key Manufacturing Milestone in the Development of its ADHD Drug CTx-1301 in Preparation for FDA Marketing Clearance

Jun 25, 2024, 9:20 AM EDT - 2 years ago

Cingulate Achieves Key Manufacturing Milestone in the Development of its ADHD Drug CTx-1301 in Preparation for FDA Marketing Clearance

Cingulate Proxy statement: Proxy Filing

Jun 18, 2024, 8:00 AM EDT - 2 years ago

Cingulate Proxy statement: Proxy Filing

Cingulate Registration statement: Registration Filing

May 17, 2024, 8:00 AM EDT - 2 years ago

Cingulate Registration statement: Registration Filing

Cingulate Reports First Quarter 2024 Financial ResultsĀ and Provides Clinical and Business Update

May 8, 2024, 7:00 AM EDT - 2 years ago

Cingulate Reports First Quarter 2024 Financial ResultsĀ and Provides Clinical and Business Update

Cingulate Quarterly report: Q1 2024

May 8, 2024, 7:00 AM EDT - 2 years ago

Cingulate Quarterly report: Q1 2024

Cingulate Earnings release: Q1 2024

May 8, 2024, 7:00 AM EDT - 2 years ago

Cingulate Earnings release: Q1 2024

Peter J. Werth, Successful Pharma Entrepreneur, Philanthropist, Cingulate Investor and Board Member, to be Featured with Chairman and CEO Shane J. Schaffer on Benzinga All Live Access

Apr 30, 2024, 5:45 AM EDT - 2 years ago

Peter J. Werth, Successful Pharma Entrepreneur, Philanthropist, Cingulate Investor and Board Member, to be Featured with Chairman and CEO Shane J. Schaffer on Benzinga All Live Access

Cingulate Proxy statement: Proxy Filing

Apr 26, 2024, 8:00 AM EDT - 2 years ago

Cingulate Proxy statement: Proxy Filing

Cingulate Proxy statement: Proxy Filing

Apr 26, 2024, 8:00 AM EDT - 2 years ago

Cingulate Proxy statement: Proxy Filing

Cingulate to Participate in Planet MicroCap Showcase: Vegas 2024

Apr 16, 2024, 5:00 PM EDT - 2 years ago

Cingulate to Participate in Planet MicroCap Showcase: Vegas 2024

Cingulate Inc. Reports Fourth Quarter and Full Year 2023 Financial ResultsĀ and Provides Clinical and Business Update

Apr 1, 2024, 8:00 AM EDT - 2 years ago

Cingulate Inc. Reports Fourth Quarter and Full Year 2023 Financial ResultsĀ and Provides Clinical and Business Update

Cingulate Annual report: Q4 2023

Apr 1, 2024, 7:00 AM EDT - 2 years ago

Cingulate Annual report: Q4 2023

Cingulate Earnings release: Q4 2023

Apr 1, 2024, 7:00 AM EDT - 2 years ago

Cingulate Earnings release: Q4 2023

Cingulate to Attend DCAT Week 2024 in New York City

Mar 6, 2024, 6:45 AM EST - 2 years ago

Cingulate to Attend DCAT Week 2024 in New York City

Cingulate Appoints Jay Roberts, Bryan Lawrence, and Jeff Ervin to its Board of Directors

Feb 13, 2024, 6:45 AM EST - 2 years ago

Cingulate Appoints Jay Roberts, Bryan Lawrence, and Jeff Ervin to its Board of Directors

Cingulate Announces Closing of $7.5 Million Public Offering

Feb 6, 2024, 4:15 PM EST - 2 years ago

Cingulate Announces Closing of $7.5 Million Public Offering

Cingulate Announces Pricing of $7.5 Million Public Offering

Feb 2, 2024, 9:15 AM EST - 2 years ago

Cingulate Announces Pricing of $7.5 Million Public Offering

Longtime Cingulate Controller Jennifer Callahan Promoted to CFO

Jan 29, 2024, 8:00 AM EST - 2 years ago

Longtime Cingulate Controller Jennifer Callahan Promoted to CFO

Cingulate Registration statement: Registration Filing

Jan 29, 2024, 7:00 AM EST - 2 years ago

Cingulate Registration statement: Registration Filing

Werth Family Investment Associates Converts Remaining $3.3M of Debt and Accrued Interest into Cingulate Equity at Premium to Market

Jan 29, 2024, 6:45 AM EST - 2 years ago

Werth Family Investment Associates Converts Remaining $3.3M of Debt and Accrued Interest into Cingulate Equity at Premium to Market

Cingulate Registration statement: Registration Filing

Jan 12, 2024, 7:00 AM EST - 2 years ago

Cingulate Registration statement: Registration Filing

Cingulate's stock skyrockets again, as ADHD treatment developer as delisting is delayed pending a February hearing

Dec 28, 2023, 7:19 AM EST - 2 years ago

Cingulate's stock skyrockets again, as ADHD treatment developer as delisting is delayed pending a February hearing

Cingulate Receives Guidance from FDA on Path Forward for Anxiety Asset CTx-2103 (buspirone)

Dec 1, 2023, 9:00 AM EST - 2 years ago

Cingulate Receives Guidance from FDA on Path Forward for Anxiety Asset CTx-2103 (buspirone)

Cingulate Registration statement: Registration Filing

Nov 15, 2023, 7:00 AM EST - 2 years ago

Cingulate Registration statement: Registration Filing

Cingulate Inc. Reports Third Quarter 2023 Financial ResultsĀ and Provides Clinical and Business Update

Nov 13, 2023, 4:15 PM EST - 2 years ago

Cingulate Inc. Reports Third Quarter 2023 Financial ResultsĀ and Provides Clinical and Business Update

Cingulate Quarterly report: Q3 2023

Nov 13, 2023, 7:00 AM EST - 2 years ago

Cingulate Quarterly report: Q3 2023

Cingulate Earnings release: Q3 2023

Nov 13, 2023, 7:00 AM EST - 2 years ago

Cingulate Earnings release: Q3 2023

Cingulate to Host CNS Key Opinion Leader Panel in New York City

Oct 17, 2023, 2:22 PM EDT - 3 years ago

Cingulate to Host CNS Key Opinion Leader Panel in New York City

Cingulate Proxy statement: Proxy Filing

Oct 2, 2023, 8:00 AM EDT - 3 years ago

Cingulate Proxy statement: Proxy Filing

Cingulate Proxy statement: Proxy Filing

Sep 22, 2023, 8:00 AM EDT - 3 years ago

Cingulate Proxy statement: Proxy Filing

Cingulate Inc. to Present at the LD Micro Main Event XVI

Sep 21, 2023, 1:30 PM EDT - 3 years ago

Cingulate Inc. to Present at the LD Micro Main Event XVI

Cingulate Inc. To Present at the LD Micro Main Event XVI

Sep 21, 2023, 11:23 AM EDT - 3 years ago

Cingulate Inc. To Present at the LD Micro Main Event XVI

Cingulate Announces Closing of $4.0 Million Public Offering

Sep 13, 2023, 4:15 PM EDT - 3 years ago

Cingulate Announces Closing of $4.0 Million Public Offering

Cingulate Announces Pricing of $4.0 Million Public Offering

Sep 11, 2023, 9:22 AM EDT - 3 years ago

Cingulate Announces Pricing of $4.0 Million Public Offering

Spicy_Weeklies
Spicy_Weeklies Aug. 2 at 2:35 AM
$CING šŸ‚
0 Ā· Reply
Spicy_Weeklies
Spicy_Weeklies Aug. 2 at 2:35 AM
$CING Canā€™t wait for the day I wake up and this stock is up multi X. šŸ¤¤
0 Ā· Reply
ZacksResearch
ZacksResearch Jul. 31 at 2:25 PM
$CING just cleared a major credibility milestone šŸš€ Phase 3 results for CTx-1301 were published in a peer-reviewed journal, reinforcing its efficacy and safety profile as the company advances toward potential regulatory approval and commercialization. šŸ“Š All three dose groups beat placebo on the primary endpoint at Week 5 āœ… Clinically meaningful improvements in ADHD symptoms with a favorable safety profile šŸ’Š Once-daily treatment candidate powered by Precision Timed Releaseā„¢ (PTRā„¢) technology See what Wall Street expects next šŸ‘‰ https://www.zacks.com/stock/research/CING/price-target-stock-forecast?cid=sm-stocktwits-0-price_target-oc-39056&ADID=SYND_STOCKTWITS_TWEET_0_PRICETARGET_OC_39056
0 Ā· Reply
Merlintrader
Merlintrader Jul. 31 at 10:11 AM
$CING Cingulate Inc. Stock Hub: CTx-1301 Phase 3 Publication, the FDA CRL, Resubmission Timeline and Risks https://www.merlintrader.com/cingulate-inc-stock-hub/
0 Ā· Reply
Spicy_Weeklies
Spicy_Weeklies Jul. 30 at 9:36 PM
$CING https://www.linkedin.com/posts/indegene_were-excited-to-announce-bryan-downey-%F0%9D%97%96%F0%9D%97%B5%F0%9D%97%B6%F0%9D%97%B2%F0%9D%97%B3-activity-7487846833537302529-_TNo?utm_source=share&utm_medium=member_ios&rcm=ACoAAARnNc4BidxrJhqoExzyhnHvJzYovDFPXTs
0 Ā· Reply
LeoWhite961
LeoWhite961 Jul. 30 at 8:43 PM
$CING published Phase 3 ADHD trial results in a peer-reviewed journal. The study adds another layer of validation for Cingulateā€™s approach, but the next step is turning clinical data into commercial progress. In biotech, execution after the trial is just as important as the trial itself.
0 Ā· Reply
Hrk024
Hrk024 Jul. 30 at 8:04 PM
$CING "It's going to $3" Absolute šŸ¤”'s! Lol. Most of the swing traders are gone in my opinion so your little bear talk tactics are a joke and are not working. We will hang around here for time being and I'm perfectly okay with it.
1 Ā· Reply
prismmarketview
prismmarketview Jul. 30 at 5:59 PM
$CING Phase 3 pediatric ADHD data for onceā€‘daily CTxā€‘1301 are now published in a top child/adolescent psychopharm journal. Peerā€‘reviewed validation of earlier topline efficacy and safety results. #CING #StimulantTherapy #ChildPsychiatry https://prismmarketview.com/cingulates-phase-3-ctx-1301-adhd-results-published-in-leading-child-adolescent-psychiatry-journal/
0 Ā· Reply
Spicy_Weeklies
Spicy_Weeklies Jul. 30 at 3:37 PM
$CING Iā€™ve parked some patient money here and will hold out for the binary outcome. Not going to try and time anything based on how close they are to the finish line. The science works and the CMC issues are most likely solvable with timeline being the main variable. Demand for a solution like this will be strong, and I believe they could leverage AI tools to cut through some of the documentation enhancements. Iā€™m assuming modest competence in the teams that are working on the remediation work. Good luck to all. Fortune favors the brave.
0 Ā· Reply
RNJen
RNJen Jul. 30 at 12:55 PM
$CING KANSAS CITY, Kan. , July 30, 2026 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING ), a biopharmaceutical company utilizing its proprietary Precision Timed Releaseā„¢ (PTRā„¢) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, announced today that Phase 3 clinical trial results for its lead asset, CTx-1301 (dexmethylphenidate HCl), for the treatment of attention-deficit/hyperactivity disorder (ADHD), have been published in the Journal of Child and Adolescent Psychopharmacology and are now available through open access. The peer-reviewed publication helps establish the efficacy and safety profile of CTx-1301 and reinforces the potential of Cingulateā€™s Precision Timed Releaseā„¢ (PTRā„¢) platform technology, as the Company advances its lead asset toward potential regulatory approval and commercialization. The manuscript represents an important addition to the scientific literature supporting next-generation ADHD
1 Ā· Reply
ccledez
ccledez Jul. 29 at 5:41 PM
$CING according to Gemini Even though grce already completed their type a meeting, as far as who will resubmit NDA 1st Cing first $GRCE 2nd $UNCY 3rd Ai is wrong sometimes
0 Ā· Reply
activehybrid
activehybrid Jul. 29 at 2:33 AM
$CING
0 Ā· Reply
buymoremakemore
buymoremakemore Jul. 28 at 10:39 PM
$CING Moar competition. Dopaine, norepinepherine, and serotonin reuptake inhibitor. So not only are attention, hyperactivity, and impulses accounted for, but also mood, executive function and emotions. https://www.fiercepharma.com/pharma/fda-approves-otsuka-adhd-drug-simtriyo-teeing-its-next-major-cns-launch
1 Ā· Reply
jinzhou5042
jinzhou5042 Jul. 28 at 9:08 PM
$CING This will be a beast
1 Ā· Reply
activehybrid
activehybrid Jul. 28 at 6:06 PM
$CING
0 Ā· Reply
EFhutton420
EFhutton420 Jul. 28 at 2:23 PM
$CING Shane really shit the bed on this one lol. It wants a 2 handle. It'll get it before the quarter is done. Could be a nice short.
0 Ā· Reply
biotechs2021
biotechs2021 Jul. 28 at 10:24 AM
$SLS $CING cmon letā€™s get back up!!! Enough already šŸ¤£
1 Ā· Reply
SolidFury
SolidFury Jul. 28 at 8:24 AM
$CING A reminder that this place usually has people pushing agendas, often misrepresenting positions, data or sometimes outright fabricating scenarios. The reality of the situation is, companies typically hold off on committing to a date until the FDA classifies the resubmission as Class 1 (~2-month review) or Class 2 (~6-month review). Cingulate has kept giving qualitative updates: CMC work underway with their manufacturing partner, no safety/efficacy concerns raised. So it's all rather standard practice so far. And remember, do your own research, fact check everything, even this post.
1 Ā· Reply
Gojaime69
Gojaime69 Jul. 28 at 2:59 AM
$CING The resubmission lack of news is concerning.
3 Ā· Reply
NJLinvestor
NJLinvestor Jul. 27 at 8:44 PM
$CING I'm sure Mr Bryan Downey the Chief Commercial Officer (CCO) of Cingulate who was appointed to the position in November 2025 to lead commercial launch preparations for the company's lead ADHD treatment candidate can handle the duties of the CLO if required to get product to market. We're in good hands.
1 Ā· Reply
fullobullz
fullobullz Jul. 27 at 8:07 PM
$CING Disappointed with management here. Was expecting some kind of guidance by now but instead all we hear is crickets. That by itself isnt to alarming but not very responsible to shareholders either. We wont see approval until next year. Im certain of that. My biggest question is how bad the dilution will be. They still have a ton left with ATM and other offerings.
1 Ā· Reply
ccledez
ccledez Jul. 27 at 12:34 PM
$GRCE $CING $UNCY At least our drug works, it's just a matter of finding the right manufacturer. We'll be all right
3 Ā· Reply